Bladder urothelial carcinoma (BLCA) is a molecularly heterogeneous malignancy with substantial unmet needs in risk stratification and therapeutic optimization. While the urinary microbiome has emerged as a critical modulator of cancer biology, its systems-level integration with host genomic, transcriptomic, and immune multi-omics data remains poorly characterized. We performed an integrative in silico analysis of 412 muscle-invasive bladder cancers from The Cancer Genome Atlas (TCGA-BLCA), combining curated microbial abundance profiles with host transcriptomic, epigenomic, mutational, immune deconvolution, and clinical survival data. Differential abundance analysis, Spearman correlation networks, Gene Set Enrichment Analysis, and machine-learning-based prognostic modeling were employed to identify microbe-host interaction landscapes and evaluate clinical translational potential. We identified profound microbial dysbiosis in tumor tissues, with Paenibacillus (31.1-fold enrichment, P = 2.56 × 10-6) and Prevotella (19.0-fold enrichment, P = 2.60 × 10-3) dominating the tumor microenvironment, while commensal genera, including Lactobacillus, Arthrobacter, and Gemella, were significantly depleted. Paenibacillus exhibited strong negative correlations with oncogenic drivers MYC (Spearman Correlation Coefficient (SCC) = -0.506), ESR1 (SCC = -0.491), and AR (SCC = -0.458), suggesting tumor-suppressive mechanisms through metabolic and immune modulation. Conversely, Prevotella demonstrated bidirectional modulation of host genes, implicating pro-inflammatory and epithelial-mesenchymal transition pathways. Multi-omics integration revealed that microbial signatures stratified TCGA molecular subtypes, immune phenotypes, and clinical outcomes. A microbiome-informed prognostic model achieved superior predictive accuracy (AUC = 0.847) compared to clinical variables alone, with validation across four independent cohorts (combined HR = 0.65, 95% CI: 0.52-0.81, P < 0.001). This study establishes a comprehensive framework for microbiome-host interactions in BLCA, identifying Paenibacillus and Prevotella as opposing microbial orchestrators of tumor biology. These findings advance bladder cancer microbiome research from descriptive taxonomy toward the development of mechanistic, clinically actionable biomarkers for precision oncology.
Ahmed Kabrah· Journal of Pure and Applied...· 0 citations
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent social communication deficits and restricted, repetitive behaviors. Gastrointestinal symptoms are common and often correlate with symptom severity, implicating the microbiota–gut–brain axis as a potential mechanism linking gut dysbiosis with neurodevelopment through neural, immune, endocrine, and metabolic pathways. This review summarizes current evidence on alterations in the gut microbiota in ASD and critically examines whether these changes contribute to disease pathogenesis or represent secondary effects. It highlights recent advances in multi-kingdom microbiome profiling, metabolomics, mechanistic studies of neuroinflammation, and neurotransmitter signaling and considers major confounding factors, including diet, medication, and gastrointestinal comorbidities. Emerging studies emphasize microbial function over taxonomy. In the largest multi-kingdom analysis, 31 microbial and functional markers distinguished children with ASD from neurotypical controls with an area under the curve of 0.91, driven primarily by ubiquinol-7 and thiamine diphosphate biosynthesis pathways rather than individual taxa. Metabolomic and genetic studies suggest that microbial metabolites may mediate behavioral effects. Microbiota transfer therapy and fecal microbiota transplantation have demonstrated sustained improvements in gastrointestinal and behavioral outcomes, whereas probiotics and dietary interventions have produced inconsistent results. Although alterations in the gut microbiome are consistently observed in ASD, specific microbial signatures remain heterogeneous, and causality remains unproven. Functional microbial pathways appear more informative than taxonomic composition for biomarker discovery and therapeutic development. Future progress requires prospective birth cohorts, pre-diagnostic sampling, mechanistic validation, and adequately powered randomized trials before microbiome-based diagnostics and therapies can be translated into clinical practice.
Ahmed Kabrah, Saad Alghamdi, Anmar A. Khan et al.· Journal of Disability Resear...· 0 citations